Research

Our work is motivated by the vision to integrate one health and equality to anti-infectives discovery and use. We do top-level science to improve future antibacterial and anti-parasitic therapies, aiming to improve access to medicines, antimicrobial stewardship, and sustainable use of biodiversity and traditional knowledge to manage infectious diseases.

We are experts in medicinal plants and plant-derived metabolites, using them to reveal pathogen-host interactions and as contextually relevant antimicrobials for low-resource settings. We work with Caenorhabditis elegans, making use of it as in vivo drug research model and by investigating its VEGF homolog.s.

 

Plant metabolites as a tool for understanding bacterial infections and driving anti-infective innovations

We study anti-infective properties of plant-derived compounds, considering both direct antibacterial (growth-limiting) and antivirulence (suppression of microbial disease-causing features) properties of the plant metabolites. In Chlamydia research, we have successfully used this approach to elucidate previously unknown pathogen-host interaction mechanisms. One example on this line of research is the knowledge gained on the role of host glutathione pools in chlamydial intracellular survival (Ylätalo et al. 2025), originally identified through antichlamydial properties of dibenzocyclooctadiene lignans from a traditional Chinese medicinal plant Schisandra chinensis (Taavitsainen et al. 2020). Similarly, studying antichlamydial properties of pine and citrus -derived monoterpenes led us to discover the significance of host isoprenoid metabolism in the chlamydial life cycle (Cebollada et al. 2026), leading to currently ongoing research on repurposing and mechanistic studies on a clinically approved prenyltransferase inhibitor as antibiotic adjuvant.

 

Our recent research also demonstrates that plants can serve as a source of innovative anti-infective agents with potential added value over current antibiotics. We recently identified a mixture of plant metabolites which prevents the growth of multiresistent bacteria at similar concentrations as clinically used antibiotics but shows remarkably lower tendency for inducing resistance in the bacteria (Reigada et al. 2025). Our current hypothesis on the exceptionally low resistance-inducing profile links to its presumed multi-target mechanism of action, and  our ongoing omics workflow aims at the identification of the underlying bacterial target combination. Outcomes of this work are expected to enable target-based discovery approach for a new generation of low-resistance pressure antibacterial agents.

 

Medicinal plant research to promote access to health in the global south

Besides applying plant-derived compounds as a resource of innovative anti-infective drug discovery and as basic research tools to understand bacteria-host interactions, our research addresses plants as a contextually relevant approach for infection management. We run research and capacity building projects in collaboration with West African researchers, aiming to bring scientific rigor to promote evidence-based use of local medicinal plants. This work is motivated by the fact that despite Sub-Saharan Africa bears globally one of the highest AMR burden, the fragile nature of the local health systems makes surveillance and stewardship -based AMR mitigation strategies unfeasible, calling for more contextually relevant approaches. Our work combines ethnobotanical surveys with experimental efficacy and safety evaluation of the prioritized plant species, involving traditional medicine practitioners and local governmental actors as key stakeholders. Examples on this line of research include 1) the profiling of the above-mentioned potent, low resistance profile plant preparation for managing wound infections and 2) an ethnopharmacology study on the management of sexually transmitted infections followed by experimental evaluation of the antichlamydial activity of the plant species most frequently cited by traditional medicine practitioners.

 

Chlamydia research: tackling diagnostic and treatment challenges

C. pneumoniae and C. trachomatis are obligate intracellular human pathogens. The better-known C. trachomatis is worldwide the most prevalent sexually transmitted bacterium, C. pneumoniae on the other hand is the causative agent for upper and lower respiratory tract infections. Both members of the chlamydial family cause primarily asymptomatic infections, but undetected infections might have detrimental effects; stressors like the administration of beta-lactam antibiotics or activation of the host immune system interrupt the chlamydial development cycle, but these so-called persister bacteria, which do not response to antibiotic treatment, readily resume replication when stressors cease. This leads to recurring symptoms, prolonged inflammation, and tissue scarring, and whereas adverse outcomes of persistent C. trachomatis infections are e.g., pelvic inflammatory disease, epididymitis, ectopic pregnancy, or infertility, C. pneumoniae might be associated with a range of chronic inflammatory diseases e.g., atherosclerosis or Alzheimer disease. However, molecular mechanisms of persistence are poorly understood, and treatment as well as diagnostics of persistent infections is lacking.

In our research, we tackle this problem from all angles: We developed and validated a highly sensitive digital PCR assay and an even more sensitive, nested PCR  method for the detection of C. pneumoniae from blood (Kaudela et al. 2026). Furthermore, we explore extracellular vesicles as a so-far uncharacterized pathogen-host mechanism for C. pneumoniae persistence, as these tiny extracellular bodies contain situational cargo and mediate intricate cell-cell communication. Extracellular vesicles not only provide a new window into chlamydial biology and pathogen-host interactions, they might also potentially serve as biomarkers for active and/or persistent infections. In an ongoing project, we characterize the protein and RNA cargo of these vesicles. In another line of research, we evaluate remedies from traditional Chinese and African medicine for their antichlamydial properties.

 

Utilizing C. elegans to understand pathogenic nematodes

In addition to medicinal plants, we investigate nematode-derived vascular endothelial growth factor (VEGF)-like proteins. Homologous to human VEGF proteins involved in the development of blood and lymphatic vessels, these VEGF-like proteins of unknown function are found in nematodes, including the model organism Caenorhabditis elegans (C. elegans), despite their lack of blood and lymphatic vasculature.

Parasitic filarial nematodes cause lymphatic filariasis, a neglected tropical disease affecting millions of people worldwide. By invading and disrupting the host's lymphatic system, these parasites can cause severe lymphoedema and long-term disability. Current treatments have limited efficacy against adult parasites and cannot reliably reverse established lymphatic remodeling, highlighting the need for novel therapeutic approaches.

Our research aims to elucidate the functions of nematode-derived VEGF-like proteins and investigate their potential interactions with host proteins. By advancing our understanding of parasite biology and host–parasite interactions, this work may help identify novel targets for future treatments of parasitic diseases. In addition, we will explore the potential of C. elegans as an alternative platform for producing complex proteins for biomedical research, with possible applications in biotechnology and drug development.